GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%21-09-2021
21-09-2021
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%21-09-2021
Glenmark Pharmaceuticals Ltd - 532296 - Intimation Of Buyback By Glenmark Pharmaceuticals Limited (The "Company") In Respect Of The Outstanding US$76,750,000 2.00% Resettable Onward Starting Equity-Linked Securities Due 2022 (The "FCC Bonds")
Intimation of buyback by Glenmark Pharmaceuticals Limited (the "Company") in respect of the outstanding US$76,750,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022 (the "FCC Bonds")15-09-2021
Glenmark Pharma concludes study on Covid drug Favipiravir in India
Drug firm Glenmark Pharmaceuticals on Wednesday said it has successfully completed its post-marketing surveillance study on Favipiravir in India.15-09-2021
Covid-19 drug Favipiravir safe, effective, says Glenmark
Favipiravir was used to treat patients with moderate to mild Covid-19.On 19 June 2020, Glenmark Pharmaceuticals received the restricted emergency use approval from the DCGI for Favipiravir (FabiFlu)15-09-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu(r)) in 1000+ COVID-19 patients, findings reinforce the drug's safety and efficacy in real world settings15-09-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of Notice of 43rd Annual General Meeting, E-voting Information and Book Closure30-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Notice Of 43Rd Annual General Meeting Of The Company For FY 2020-21 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Further to our letter dated August 24, 2021 and pursuant to Regulation 30 of the Listing Regulations, enclosed please find herewith the Notice and Explanatory statement Convening the 43rd Annual General Meeting (AGM) scheduled to be held on Friday, September 24, 2021 at 2.00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).27-08-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Reg. 34 (1) Annual Report
Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the Annual Report for the Financial Year 2020-21. The Secretarial Audit Report of Indian material unlisted subsidiary is also attached. The Annual Report is being sent through electronic mode to all those members whose e-mail ids have been registered with the Company/ Depository Participant/ Registrar and Transfer Agent and the same is also being made available on the website of the Company, at: https://www.glenmarkpharma.com/sites/defau1t/files/ANNUAL_REPORT_2021.pdf Request you to kindly take the same on record .27-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Intimation Of The Date Of 43Rd Annual General Meeting And Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We have to inform you that the 43rd Annual General Meeting (AGM) of Members of the Company is scheduled to be held on Friday, September 24, 2021 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio Visual Means (''OAVM"). The copy of the notice will be sent to you in due course. Pursuant to the Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Friday, September 10, 2021 to Friday, September 24, 2021 (both days inclusive) for the purpose of the AGM and determining the names of the eligible Members for equity dividend.24-08-2021